Aquestive CEO sells 25,000 shares in open market

Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 25,000 shares of common stock.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 25,000 shares of common stock. The shares were sold at a weighted average price of $4.1604 per share, within a range from $4.14 to $4.235 per share.

After this transaction, Barber directly holds 635,574 shares of Aquestive Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 25,000 shares

Net Sell 1 txn

Insider Barber Daniel

Role President and CEO

Sold 25,000 shs ($104K)

Type	Security	Shares	Price	Value
Sale	Common Stock	25,000	$4.1604	$104K

Holdings After Transaction: Common Stock — 635,574 shares (Direct)

Footnotes (1)

F1. The reported transaction involves sale transactions from $4.14 to $4.235 per share. The weighted average price per share was $4.1604. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 25,000 shares Weighted average sale price: $4.1604 per share Sale price range: $4.14 to $4.235 per share +1 more

4 metrics

Shares sold 25,000 shares Open-market sale of common stock by CEO Daniel Barber

Weighted average sale price $4.1604 per share Average price for the 25,000 shares sold

Sale price range $4.14 to $4.235 per share Range of prices for individual sale transactions

Shares held after transaction 635,574 shares CEO Daniel Barber’s direct ownership following the sale

Key Terms

open-market sale, weighted average price per share, Form 4, SEC staff

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

SEC staff regulatory

"provide upon request by the SEC staff, the Issuer or a security holder"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aquestive Therapeutics (AQST) report on this Form 4?

Aquestive Therapeutics reported that President and CEO Daniel Barber sold 25,000 shares of common stock in an open-market transaction. This filing discloses the trade size, pricing details, and Barber’s updated direct ownership position after the sale.

How many Aquestive Therapeutics (AQST) shares does CEO Daniel Barber own after the sale?

After the reported open-market sale, CEO Daniel Barber directly holds 635,574 shares of Aquestive Therapeutics common stock. This figure reflects his remaining stake following the 25,000-share disposition disclosed in the Form 4 insider trading report.

At what price did the Aquestive Therapeutics (AQST) CEO sell his shares?

Daniel Barber’s 25,000 Aquestive Therapeutics shares were sold at prices ranging from $4.14 to $4.235 per share. The weighted average sale price was $4.1604 per share, as disclosed in the Form 4 filing’s footnote explanation.

Was the Aquestive Therapeutics (AQST) CEO’s trade an open-market sale?

Yes. The transaction is identified as an open-market sale of common stock. The Form 4 classifies it under transaction code “S,” which represents a sale in the open market or a private transaction, and provides detailed pricing information for the shares sold.

Does the Aquestive Therapeutics (AQST) Form 4 detail the price breakdown of shares sold?

The filing states that shares were sold in multiple transactions between $4.14 and $4.235 per share, with a weighted average of $4.1604. It notes that detailed trade-by-trade price information is available upon request from the company, the SEC staff, or shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/16/2026 - 04:09 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barber Daniel

(Last)

(First)

(Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN

NEW JERSEY

07059

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		S		25,000	D	$4.1604⁽¹⁾	635,574	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported transaction involves sale transactions from $4.14 to $4.235 per share. The weighted average price per share was $4.1604. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR